Welcome to our dedicated page for Xenon Pharmaceut SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xenon Pharmaceuticals Inc. filings document a Nasdaq-listed Canadian biopharmaceutical issuer developing ion channel modulators for neurological and psychiatric disorders. Recent Form 8-K reports cover operating results, Regulation FD clinical disclosures, azetukalner study updates, investor presentation materials and exhibits tied to company press releases.
The filing record also includes proxy materials for shareholder voting and executive compensation, amendments to inducement equity incentive plans, registration and prospectus materials for common-share sales, pre-funded warrant and underwriting agreements, at-the-market offering disclosures, and capital-structure information for XENE common shares.
Xenon Pharmaceuticals Inc. announced via press release dated August 11, 2025 that it is furnishing its financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1 and, per the filing, the information is furnished to the SEC rather than filed.
The company reiterates that it distributes material information through SEC filings, press releases, conference calls, its corporate and investor websites, and social media channels. The filing identifies the company trading as XENE on the Nasdaq Global Market and is signed by Ian Mortimer, Chief Executive Officer and Interim Chief Financial Officer.
Filing: Schedule 13G/A by FMR LLC and Abigail P. Johnson reporting beneficial ownership in XENON PHARMACEUTICALS INC (CUSIP 98420N105). The statement reflects an event date of 06/30/2025 and signature dated 08/05/2025.
Holdings: Aggregate beneficial ownership is 8,824,363 shares, representing 11.5% of the class. On the cover data FMR LLC reports sole voting power of 8,824,348, sole dispositive power of 8,824,363, and zero shared voting/dispositive power. Abigail P. Johnson is reported with sole dispositive power of 8,824,363 and no voting power shown. The filing states the securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer. Exhibit 99 and Exhibit 24 (power of attorney) are referenced.
Form 3 overview: On 25 June 2025, Xenon Pharmaceuticals Inc. (XENE) filed an Initial Statement of Beneficial Ownership (Form 3) on behalf of newly disclosed officer Darren S. Cline, Chief Commercial Officer. The filing reports the event date as 23 June 2025 and confirms Mr. Cline’s Section 16 insider status.
Key disclosure: Both Table I (non-derivative holdings) and Table II (derivative holdings) state "No securities are beneficially owned,” meaning Mr. Cline presently holds zero shares or options of Xenon. No amendments, joint filings, or indirect ownership structures are noted. The document is therefore a procedural compliance filing rather than a transaction or compensation event and contains no financial metrics, option grants, or purchase details.
For investors, the absence of insider ownership could be interpreted as a lack of immediate equity alignment, but the filing primarily signals timely regulatory compliance following Mr. Cline’s appointment.